Iluvien

Fluocinolone Acetonide, the active ingredient in Iluvien, is a corticosteroid presented as a 0.19 mg intravitreal sustained‑release implant for intravitreal use. It treats diabetic macular edema and chronic non‑infectious posterior uveitis in adult patients.

GNH USA supplies Iluvien as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

Iluvien (fluocinolone acetonide) is used to manage ocular inflammatory conditions and retinal edema.

Diabetic macular edema: reduces retinal swelling and improves visual acuity. Chronic non‑infectious posterior uveitis: controls intra‑ocular inflammation and prevents vision loss. Uveitis‑associated macular edema: helps resolve swelling linked to intra‑ocular inflammation.

Adverse ocular reactions may occur following Iluvien implantation.

Common Side Effects: - Increased intraocular pressure: may require topical therapy. - Cataract formation: accelerated lens opacity in phakic eyes. - Blurred vision: transient visual disturbance after insertion. - Vitreous floaters: perception of moving spots.

Serious or Rare Side Effects: - Endophthalmitis: intraocular infection requiring urgent treatment. - Retinal detachment: separation of retinal layers. - Persistent elevated IOP needing surgical intervention. - Implant migration: displacement of the device within the eye.

Prior to Iluvien implantation, clinicians should evaluate ocular health and systemic factors.

Patient selection: assess glaucoma risk and baseline intraocular pressure. Infection risk: avoid use in active ocular infection. Pregnancy: safety unknown; use only if benefit outweighs potential risk. Concurrent systemic steroids: consider additive immunosuppressive effects. Monitor IOP: schedule regular ophthalmic examinations post‑implant. Store at ambient temperature: keep in original packaging, protect from moisture and light.

Fluocinolone acetonide implants may interact with other ocular or systemic therapies.

Major Interactions (Avoid): - Other intravitreal corticosteroids: additive risk of ocular hypertension. - Recent ocular surgery (within 6 weeks): increased wound‑healing complications.

Moderate Interactions (Monitor Closely): - Systemic CYP3A4 inhibitors (e.g., ketoconazole): may raise intraocular steroid levels. - Systemic immunosuppressants (e.g., cyclosporine): heightened infection risk. - Antiglaucoma medications: may require dosage adjustment.